Affordability of newer antiseizure medications in Asian resource‐limited countries

One of the objectives of the Intersectoral Global Action Plan on epilepsy and other neurological disorders for 2022 to 2031 is to ensure at least 80% of people with epilepsy (PWE) will have access to appropriate, affordable, and safe antiseizure medications (ASMs) by 2031. However, ASM affordability is a significant issue in low‐ and middle‐income countries, preventing PWE from accessing optimal treatment. This study aimed to determine the affordability of the newer (second and third generation) ASMs in resource‐limited countries in Asia.

[1]  M. Brodie,et al.  Development and Validation of a Deep Learning Model for Predicting Treatment Response in Patients With Newly Diagnosed Epilepsy. , 2022, JAMA neurology.

[2]  A. Nasim,et al.  Evaluation of Availability, Prices, and Affordability of Selected Essential Medicines in Balochistan, Pakistan , 2022, International Journal of Public Health.

[3]  E. Beghi,et al.  The global cost of epilepsy: A systematic review and extrapolation , 2022, Epilepsia.

[4]  M. Ryan,et al.  Barriers to generic antiseizure medication use: Results of a global survey by the International League Against Epilepsy Generic Substitution Task Force , 2022, Epilepsia open.

[5]  E. Beghi,et al.  Survey on the worldwide availability and affordability of antiseizure medications: Report of the ILAE Task Force on Access to Treatment , 2022, Epilepsia.

[6]  M. Sperling,et al.  The EpiPick algorithm to select appropriate antiseizure medications in patients with epilepsy: Validation studies and updates , 2021, Epilepsia.

[7]  P. Preux,et al.  Availability, affordability, and quality of essential anti‐seizure medication in Cambodia , 2021, Epilepsia open.

[8]  P. Preux,et al.  Availability, affordability, and quality of essential antiepileptic drugs in Lao PDR , 2020, Epilepsia open.

[9]  J. Goraya,et al.  Antiepileptic Drug Prices, Availability and Affordability in a Resource-Limited Setting , 2020, Annals of Indian Academy of Neurology.

[10]  Z. Saleem,et al.  Evaluation of prices, availability and affordability of essential medicines in Lahore Division, Pakistan: A cross-sectional survey using WHO/HAI methodology , 2019, PloS one.

[11]  C. Murray,et al.  On the road to universal health care in Indonesia, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet.

[12]  Patrick Kwan,et al.  Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs: A 30-Year Longitudinal Cohort Study , 2017, JAMA neurology.

[13]  L. Wilkins.  Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies , 2017, Neurology.

[14]  C. Wanigatunge,et al.  A national survey on availability, price and affordability of selected essential medicines for non communicable diseases in Sri Lanka , 2014, BMC Public Health.

[15]  W. Brouwer,et al.  Measuring the affordability of medicines: importance and challenges. , 2013, Health policy.

[16]  M. Bianchin,et al.  Development of an online tool to determine appropriateness for an epilepsy surgery evaluation , 2013, Neurology.

[17]  Hude Quan,et al.  Development of an online tool to determine appropriateness for an epilepsy surgery evaluation , 2012, Neurology.

[18]  S. Saxena,et al.  Mapping the availability, price, and affordability of antiepileptic drugs in 46 countries , 2012, Epilepsia.

[19]  W. Brouwer,et al.  Quantifying the Impoverishing Effects of Purchasing Medicines: A Cross-Country Comparison of the Affordability of Medicines in the Developing World , 2010, PLoS medicine.

[20]  D Ross-Degnan,et al.  Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis , 2009, The Lancet.

[21]  A. Ngugi,et al.  The epilepsy treatment gap in developing countries: A systematic review of the magnitude, causes, and intervention strategies , 2008, Epilepsia.

[22]  P. Preux,et al.  Epidemiology, aetiology, and clinical management of epilepsy in Asia: a systematic review , 2007, The Lancet Neurology.

[23]  K. Lim,et al.  Epilepsy in Southeast Asia, how much have we closed the management gap in past two decades? , 2020 .

[24]  G. Madhavan,et al.  Making Medicines Affordable: A National Imperative , 2017 .

[25]  K. Hassell,et al.  Affordability of medicines and patients’ cost-reducing behaviour , 2005, Applied health economics and health policy.